Clinical Trials Logo
  1. Home
  2. Helicobacter Infection
  3. NCT00841854

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

Helicobacter Infection Clinical Trial

Official title:
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.

Clinical Trial Summary

At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact duration of bismuth based second line treatment is not determined. Therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00841854
Study type Interventional
Source Asan Medical Center
Contact
Status Completed
Phase Phase 4
Start date June 2008
Completion date November 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT02711176 - Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Phase 4
Completed NCT00656968 - Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Phase 4
Completed NCT02051348 - Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion Phase 2/Phase 3
Completed NCT02349685 - The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori N/A
Recruiting NCT01723059 - Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection N/A
Recruiting NCT02373280 - The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection N/A
Terminated NCT02359331 - The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection N/A
Completed NCT01163435 - Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication Phase 4